Trials

Correction to: SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion

Sarah Halford[1*], Susan Wan[1], Ilaria Dragoni[1], Julie Silvester[1], Bobojon Nazarov[2], Daniel Anthony[3], Suzie Anthony[4], Emma Ladds[5], John Norrie[6], Kevin Dhaliwal[6] and and the CDD SPIKE-1 Project Team[1]

Correction to: Trials 22, 550 (2021)
https://doi.org/10.1186/s13063-021-05461-9

Following the publication of the original article [1], we were notified that the Flu-iiQ™ table included in the supplementary material of original publication needs to be deleted. The authors were not at liberty to publish the table in full as a number of the items listed are confidential and commercially sensitive. For full details of the Flu-iiQ™ questionnaire please contact Measured Solutions P/L, PO Box 5127, Alphington VIC 3079, Australia (measuredsolutions.com.au).

The original article has been corrected.

Author details
[1]Cancer Research UK Centre for Drug Development, London, UK. [2]Latus Therapeutics, London, UK. [3]University of Oxford, Oxford, UK. [4]Oxford University Hospitals NHS Foundation Trust, Oxford, UK. [5]Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. [6]The University of Edinburgh, Edinburgh, UK.

Published online: 21 April 2022

Reference
1. Halford, et al. SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion. Trials. 2021;22:550. https://doi.org/10.1186/s13063-021-05461-9.

The original article can be found online at https://doi.org/10.1186/s13063-021-05461-9.

* Correspondence: sarah.halford@cancer.org.uk
[1]Cancer Research UK Centre for Drug Development, London, UK
Full list of author information is available at the end of the article